Alison Bailey, MD, FACC

Articles by Alison Bailey, MD, FACC

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

Barriers and Solutions for Lipid Management in Clinical Practice

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Multidisciplinary/Team Based Approach for Lipid Management

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 2nd 2022

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Emerging Therapies for Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC

December 2nd 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

The Role of Combination Therapy in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

Managing ASCVD in Patients With Statin Intolerance

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Use of Statins in Management of Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Achievement of LDL-C Goals in the Real World

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

Achievement of Goals in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Personalized Treatment for Patients with ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Impact of Lipid Lowering on Risk for ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Risk Enhancing Factors in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

Alison Bailey, MD, FACC

Articles by Alison Bailey, MD, FACC

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

Barriers and Solutions for Lipid Management in Clinical Practice

Multidisciplinary/Team Based Approach for Lipid Management

Emerging Therapies for Hypercholesterolemia

The Role of Combination Therapy in Hypercholesterolemia

Managing ASCVD in Patients With Statin Intolerance

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

Guideline Recommendations for Lipid Lowering

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

Use of Statins in Management of Hypercholesterolemia

Achievement of LDL-C Goals in the Real World

Achievement of Goals in ASCVD

Personalized Treatment for Patients with ASCVD

Impact of Lipid Lowering on Risk for ASCVD

Risk Enhancing Factors in ASCVD

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

Latest Updated Articles

Trending on HCPLive

The HCPFive: Top News for Healthcare Providers from the Week of 07/12

Millions of New Patients Eligible for Statins Under 2026 AHA/ACC Guidelines

Sonnenberg Breaks Down EMERGE Phase 3 Trial Design for DT120 in MDD

FDA Expands Exa-Cel (Casgevy) Approval, Bringing Gene Therapy to Younger Children

Atacicept Approval Brings BAFF/APRIL Targeting to IgAN With Richard Lafayette, MD